[go: up one dir, main page]

AR053700A1 - Antagonistas del receptor de proquineticina 2 - Google Patents

Antagonistas del receptor de proquineticina 2

Info

Publication number
AR053700A1
AR053700A1 ARP060101154A ARP060101154A AR053700A1 AR 053700 A1 AR053700 A1 AR 053700A1 AR P060101154 A ARP060101154 A AR P060101154A AR P060101154 A ARP060101154 A AR P060101154A AR 053700 A1 AR053700 A1 AR 053700A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
phenyl
proviso
alkoxy
Prior art date
Application number
ARP060101154A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR053700A1 publication Critical patent/AR053700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticos que los contienen y usos para el tratamiento de trastornos mediados por la proquineticina 2 o el receptor de proquineticina 2. Reivindicacion 1: Un compuesto de formula (1), donde: A1 es hidrogeno; arilo; heteroarilo; cicloalquilo C5-8; o heterociclilo; con la condicion de que A1 sea diferente de piridin-4-ilo, N-t-butoxicarbonil-piperidin-4-ilo, o N-metil-piperidin-3-ilo; y donde los sustituyentes de A1 diferentes de hidrogeno está opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, halogeno, nitro, alquiloC1-6-halogenado, alcoxiC1-6-halogenado, alquiltio C1-6, alcoxiC1-6-carbonilo, amino, alquilamino C1-6, di(alquilC1-6)amino, ciano, hidroxi, aminocarbonilo, alquilamino, carbonilo C1-6, di(alquilC1-6)aminocarbonilo, alcoxiC1-6carbonilamino, alquilC1-6-carbonilo, alquiltioC1-6-carbonilo, formilo, alquilsulfonilo C1-6, alquilsulfonilamino C1-6, aminosulfonilo, alquilaminosulfonilo C1-6, y di(alquilC1-6)aminonsulfonilo; L1 es -(CH2)r- o -CH2CH2X(CH2)s-, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alquenilo C2-6, alquinilo C2-6, y halogeno; con la condicion de que cuando A1 es hidrogeno, r es mayor o igual a 4; r es un numero entero de 1 a 5; s es un numero entero de 1 a 3; X es O o S; D es -P-A2; donde cuando A2 es hidrogeno, P es -(CH2)4-6-, y cuando A2 es diferente de hidrogeno, P es -(CH2)1-2- o -CH2CH=CH-; A2 es hidrogeno; benzodioxalilo; heteroarilo diferente de piridin-2-ilo no sustituido; cicloalquilo C3-8; o fenilo opcionalmente sustituido en las posiciones meta y para con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, alquilo C1-6-halogenado, alcoxiC1-6-halogenado, arilalcoxi C1-6, fenilo, alquiltio C1-6, alcoxiC1-6-carbonilo, amino, alquilamino C1-6, di(alquilC1-6)amino, ciano, hidroxi, nitro, alquilC1-6- carbonilo, alquiltioC1-6-carbonilo, aminocarbonilo, alquilaminoC1-6-carbonilo, di(alquilC1-6)aminocarbonilo, alquilC1-6-carbonilamino, y un cicloalquiloxi C3-6 no fusionado, donde benzodioxalilo, heteroarilo, y cicloalquilo C3-8 están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, alquiloC1-6-halogenado, alcoxiC1-6- halogenado, arilalcoxi C1-6, fenilo, alquiltio C1-6, alcoxiC1-6-carbonilo, amino, alquilamino C1-6, di(alquilC1-6)amino, ciano, hidroxi, nitro, alquilC1-6-carbonilo, alquiltioC1-6-carbonilo, aminocarbonilo, alquilaminoC1-6-carbonilo, di(alquilC1- 6)aminocarbonilo, alquilC1-6-carbonilamino y un cicloalquiloxi C3-6 no fusionado; con la condicion de que no más de dos sustituyentes de A2 sean arilalcoxi C1-6, fenilo o un cicloalquilo C3-6 no fusionado; con la condicion de que cuando A1 es fenilo no sustituido y L2 es -X1-CH(Rx)-(CRyRz)-, donde X1 es NH, y Rx, Ry y Rz son hidrogeno, A2 sea diferente de fenilo no sustituido; fenilo sustituido con arilalcoxi C1-6 o fenilo; o fenilo sustituido en la posicion meta con ciano; y, además con la condicion de que cuando A1 es fenilo no sustituido y L2 es -X1- CH(Rx)-(CRyRz)2-, donde X1 es NH y Rx, Ry y Rz son cada uno hidrogeno, A2 sea diferente de fenilo sustituido con metoxi; y con la condicion de que cuando A1 es 3,4-dicloro-fenilo y P es - CH2-, A2 sea diferente de fenilo sustituido en la posicion meta con trifluorometilo o trifluorometoxi; y además con la condicion de que cuando A1 es 3,4-dicloro-fenilo y P es -(CH2)2-, A2 sea diferente de 4-metoxi-fenilo; W es N o C(Rx); donde Rw es H o alquilo C1-2; L2 es un radical bivalente seleccionado del grupo que consiste en: pirrolidinilo o piperidinilo unido al anillo de triazina de formula (1) por medio de su átomo de nitrogeno, donde dicho pirrolidinilo o piperidinilo está sustituido con un átomo de carbono con -(CH2)0-2-; NH-cicloalquiloC5-7-(CH2)0-2-; con la condicion de que cuando cicloalquilo C5-7 es ciclohexilo, Q está unido a la posicion 2- o cis-4- en relacion con la posicion de -NH-; X1-alquiloC2-6-; X1-(CH2)u- X2-(CH2)v- ; donde u es un numero entero de 1 a 3; y donde v es un numero entero de 1 a 4; con la condicion de que cuando X1 es un enlace directo y W es C(Rw), entonces u es 1 y v es 2 a 4; X2-(CH2)0-4-; X1-(CH2)2-3-X3-(CH2)2-3-; NH(CH2)1-4C(=O)-, con la condicion de que al menos uno de Rb, Rc, o Rd es diferente de hidrogeno y m es 0; NHC(=O)-(CH2)1-4-; C(=O)NH(CRyRz)2-5-; y X1- CH(Rx)-(CRyRz)1-5-; de manera tal que cuando X1 es un enlace directo y W es C(Rw), entonces Rx es hidrogeno; donde X1 es - NH-, O, S, o un enlace directo, de manera tal que X1 es diferente de O cuando W es N; X2 es -CH=CH-; X3 es O, S, NH, o C=O; Rx, Ry, y Rz son independientemente H o alquilo C1-4; y con la condicion de que L2 en ningun caso exceda de 7 átomos de longitud; y además con la condicion de que cuando L2 es -X2-(CH2)0-4- o -C(=O)NH(CRyRz)2-5-, entonces Rw es hidrogeno; Q es (O)mN(Ra)-G; y m es 0 o 1; G es -C(=NRb)NRcRd; Ra y Rd son independientemente hidrogeno, alquilo C1-6, alquenilo C1-6 o alquinilo C3-6, donde los sustituyentes de Ra y Rd diferentes de hidrogeno están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en hidroxi, alcoxi C1-4, fluoro, amino, alquilamino C1-4, dialquilamino C1-4, y alquilC1-4-carbonilo; o Ra y Rc se toman junto con los átomos a los cuales están unidos para formar un anillo monocíclico de 5-8 miembros opcionalmente sustituido con oxo; Rb es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C3-6, alcoxi C3-6-carbonilo, o ciano; o Rb y Rc se toman junto con los átomos a los cuales están unidos para formar un anillo monocíclico de 5-8 miembros, opcionalmente sustituido con oxo; Rc es hidrogeno, alquilo C1-10, alquenilo C2-10, alquinilo C3-10, cicloalquilo C3-7, adamantilo, amino, alquilamino C1-6, di(alquilC1-6)amino, alquilC1-6-carbonilo, alcoxiC1-6-carbonilo, arilcarbonilo, heteroarilcarbonilo, heterociclilcarbonilo, arilo, heteroarilo o heterociclilo; donde alquilo C1- 10, alquenilo C2-10, y alquinilo C2-10 están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en hidroxi, alcoxi C1-6, trifluorometilo, arilo, heteroarilo y heterociclilo; y donde cualquier sustituyente de Rc que contiene arilo o heteroarilo está opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, alquilo C1-6-fluorado, alcoxiC1- 6-fluorado, alquilC1-6-carbonilo, alcoxiC1-6-carbonilo, aminocarbonilo, alquilaminoC1-6-carbonilo, di(alquilC1-6)aminocarbonilo, alcoxiC1-6- carbonilamino, formilo, alquilsulfonilo C1-6, alquilsulfonilamino C1-6, aminosulfonilo, alquilaminosulfonilo C1-6, y di(alquiloC1-6) aminosulfonilo, nitro, metiltio, hidroxi y ciano; o Rc y Rd se toman con los átomos a los cuales están unidos para formar un anillo monocíclico de 5-8 miembros que opcionalmente incluye 1 a 2 heteroátomos O o S en el anillo y dicho anillo está opcionalmente sustituido con oxo; con la condicion de que en cualquier caso, solo exista un anillo opcionalmente entre Ra y Rb, Rb y Rc, o Rc y Rd; y enantiomeros, diastereomeros, tautomeros, solvatos, y sus sales aceptables para uso farmacéutico.
ARP060101154A 2005-03-24 2006-03-23 Antagonistas del receptor de proquineticina 2 AR053700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66486505P 2005-03-24 2005-03-24

Publications (1)

Publication Number Publication Date
AR053700A1 true AR053700A1 (es) 2007-05-16

Family

ID=36580484

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101154A AR053700A1 (es) 2005-03-24 2006-03-23 Antagonistas del receptor de proquineticina 2

Country Status (16)

Country Link
US (1) US20080045535A1 (es)
EP (1) EP1869006A1 (es)
JP (1) JP2008534499A (es)
KR (1) KR20070116915A (es)
CN (1) CN101223147A (es)
AR (1) AR053700A1 (es)
AU (1) AU2006229791A1 (es)
BR (1) BRPI0609317A2 (es)
CA (1) CA2602510A1 (es)
EA (1) EA200702062A1 (es)
IL (1) IL186188A0 (es)
MX (1) MX2007011847A (es)
NO (1) NO20075406L (es)
TW (1) TW200716566A (es)
WO (1) WO2006104713A1 (es)
ZA (1) ZA200709147B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7748606B2 (en) 2004-06-29 2010-07-06 United States Postal Service Cluster box mail delivery unit having security features
US7968710B2 (en) 2005-03-24 2011-06-28 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists
EP1959959B1 (en) * 2005-12-06 2013-04-10 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
CN101405002A (zh) * 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
CN101495464B (zh) * 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂
CA2704185C (en) * 2007-10-30 2016-02-16 Janssen Pharmaceutica N.V. Amino-heteroaryl-containing prokineticin 1 receptor antagonists
US8722896B2 (en) 2008-12-17 2014-05-13 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
EP2399910B1 (en) * 2009-02-13 2014-04-02 Shionogi&Co., Ltd. Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them
JP2012521411A (ja) * 2009-03-26 2012-09-13 マピ ファーマ リミテッド アログリプチンの調製プロセス
JP2013530231A (ja) * 2010-06-28 2013-07-25 ヤンセン ファーマシューティカ エヌ．ベー． 鎮痛処置用プロキネチシン１受容体アンタゴニスト
WO2012006003A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
JP5594706B2 (ja) * 2010-08-10 2014-09-24 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
JP6124351B2 (ja) 2012-02-09 2017-05-10 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
MX391647B (es) 2015-04-24 2025-03-21 Shionogi & Co Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704272D0 (sv) * 1997-11-21 1997-11-21 Astra Pharma Prod Novel Compounds
DE60313350T2 (de) * 2002-08-13 2008-01-03 Warner-Lambert Company Llc Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CA2602510A1 (en) 2006-10-05
ZA200709147B (en) 2009-08-26
KR20070116915A (ko) 2007-12-11
WO2006104713A1 (en) 2006-10-05
AU2006229791A1 (en) 2006-10-05
CN101223147A (zh) 2008-07-16
IL186188A0 (en) 2008-01-20
BRPI0609317A2 (pt) 2010-03-16
MX2007011847A (es) 2008-03-11
NO20075406L (no) 2007-12-14
US20080045535A1 (en) 2008-02-21
EA200702062A1 (ru) 2008-02-28
EP1869006A1 (en) 2007-12-26
TW200716566A (en) 2007-05-01
JP2008534499A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
AR053700A1 (es) Antagonistas del receptor de proquineticina 2
AR053451A1 (es) Antagonistas del receptor de proquineticina 1
EA200501617A1 (ru) Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы
EA200601125A1 (ru) 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы
NO20063028L (no) 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
AR069512A1 (es) Pirazolopirimidinas sustituidas para el tratamiento de trastornos del snc. composiciones farmaceuticas
NO20062892L (no) 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
SE0301373D0 (sv) Novel compounds
AR069127A1 (es) Antagonistas del receptor de procineticina 1 que contienen amino-heteroarilo
PL373645A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
DK1474395T3 (da) Nicotinamidderivater, der er nyttige som p38-inhibitorer
PL375083A1 (en) Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
AR058407A1 (es) Antagonistas del receptor de proquineticina 2
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
AR014173A1 (es) Compuestos inhibidores del intercambio sodio/protones, de acil guanidina, utiles como agentes antianginales y cardioprotectores y las composicionesfarmaceuticas que los contienen
AR058406A1 (es) Antagonistas del receptor de proquineticina 1
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
WO2005047268A3 (en) Substituted pyrimidine compositions and methods of use
EA200600018A1 (ru) Производные никотинамида, полезные в качестве ингибиторов фдэ4
AR049323A1 (es) Compuestos heterociclicos nitrogenados inhibidores de igf-1r y composiciones farmaceuticas que los componen.
AR064887A1 (es) Derivados de piridopirimidina utiles como agentes terapeuticos en trastornos inflamatorios e inmunes, proceso de preparacion de los mismos y composiciones farmaceuticas que lo contienen
TW200503722A (en) Substituted 7-aza-quinazoline compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal